News | February 18, 2022
Health Canada authorizes Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
